Molecular biology of malignant mesothelioma

Environmental Health and Preventive Medicine

Volumn 13, Issue 2, 2008, Pages 65-70

  Sekido, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Asbestos; Malignant mesothelioma; Molecular target therapy; Oncogene; Tumor suppressor gene

Indexed keywords

ASBESTOS FIBER; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID ANTAGONIST; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMATOSIS TYPE 2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME 22Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; FAMILIAL CANCER; GENE INACTIVATION; GENE MUTATION; HUMAN; MALIGNANT MESOTHELIOMA; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; ONCOGENE; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 49549094680     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-007-0015-8     Document Type: Conference Paper

References (39)

1. HI Pass N Vogelzang S Hahn M. Carbone 2004 Malignant pleural mesothelioma Curr Probl Cancer 28 93 174
2. M Carbone RA Kratzke JR. Testa 2002 The pathogenesis of mesothelioma Semin Oncol 29 2 l7
3. NJ Vogelzang JJ Rusthoven J Symanowski C Denham E Kaukel P Ruffie 2003 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636 44
4. JP van Meerbeeck R Gaafar C Manegold RJ Van Klaveren EA Van Marck M Vincent 2005 Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 6881 9
5. T Murayama K Takahashi Y Natori N. Kurumatani 2006 Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model Am J Ind Med 49 1 7
6. J Peto A Decarli C La Vecchia F Levi E. Negri 1999 The European mesothelioma epidemic Br J Cancer 79 666 72
7. BW Robinson RA. Lake 2005 Advances in malignant mesothelioma N Engl J Med 353 1591 1603
8. BW Robinson AW Musk RA. Lake 2005 Malignant mesothelioma Lancet 366 397 408
9. SP Faux CE Houghton A Hubbard G. Patrick 2000 Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres Carcinogenesis 21 2275 80
10. RA Kratzke GA Otterson CE Lincoln S Ewing H Oie J Geradts 1995 Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma J Natl Cancer Inst 87 1870 5
11. JQ Cheng SC Jhanwar WM Klein DW Bell WC Lee DA Altomare 1994 p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma Cancer Res 54 5547 51
12. T Taniguchi S Karnan T Fukui T Yokoyama H Tagawa K Yokoi 2007 Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32 Cancer Sci 98 438 46
13. Y Sekido HI Pass S Bader DJ Mew MF Christman AF Gazdar 1995 Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer Cancer Res 55 1227 31
14. AB Bianchi SI Mitsunaga JQ Cheng WM Klein SC Jhanwar B Seizinger 1995 High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas Proc Natl Acad Sci USA 92 10854 8
15. ME Baser 2006 The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene Hum Mutat 27 297 306
16. DA Altomare CA Vaslet KL Skele A De Rienzso K Devarajan SC Jhanwar 2005 A mouse model recapitulating molecular features of human mesothelioma Cancer Res 65 8090 5
17. AI McClatchey M. Giovannini 2005 Membrane organization, tumorigenesis-the NF2 tumor suppressor, Merlin Genes Dev 19 2265 2277
18. H Jin T Sperka P Herrlich H. Morrison 2006 Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase Nature 442 576 9
19. F Hamaratoglu M Willecke M Kango-Singh R Nolo E Hyun C Tao 2006 The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signaling to regulate cell proliferation and apoptosis Nat Cell Biol 8 27 36
20. AF Gazdar JS Butel M. Carbone 2002 SV40, human tumours: myth, association or causality? Nat Rev Cancer 2 957 64
21. F Lopez-Rios PB Illei V Rusch M Ladanyi 2004 Evidence against a role for SV40 infection in human mesotheliomas, high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids Lancet 364 1157 66
22. R Jagadeeswaran PC Ma TY Seiwert S Jagadeeswaran O Zumba V Nallasura 2006 Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma Cancer Res 66 352 61
23. A Destro GL Ceresoli M Falleni PA Zucali E Morenghi P Bianchi 2006 EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations Lung Cancer 51 207 15
24. G Galffy KA Mohammed PA Dowling N Nasreen MJ Ward VB. Antony 1999 Interleukin 8: an autocrine growth factor for malignant mesothelioma Cancer Res 59 367 71
25. SS Murthy JR. Testa 1999 Asbestos, chromosomal deletions, tumor suppressor gene alterations in human malignant mesothelioma J Cell Physiol 180 150 7
26. T Taguchi SC Jhanwar JM Siegfried SM Keller JR Testa 1993 Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, 9p in human malignant mesothelioma Cancer Res 53 4349 55
27. BR Balsara DW Bell G Sonoda A De Rienzo S du Manoir SC Jhanwar 1999 Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma Cancer Res 59 450 4
28. M Krismann KM Muller M Jaworska G. Johnen 2002 Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry, comparative genomic hybridization of 90 cases J Pathol 197 363 71
29. NH Heintz YM Janssen BT Mossman 1993 Persistent induction of c-fos, c-jun expression by asbestos Proc Natl Acad Sci USA 90 3299 303
30. RK Thomas AC Baker RM Debiasi W Winckler T Laframboise WM Lin 2007 High-throughput oncogene mutation profiling in human cancer Nat Genet 39 347 51
31. S Singhal R Wiewrodt LD Malden KM Amin K Matzie J Friedberg 2003 Gene expression profiling of malignant mesothelioma Clin Cancer Res 9 3080 97
32. GJ Gordon GN Rockwell RV Jensen JG Rheinwald JN Glickman JP Aronson 2005 Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling Am J Pathol 166 1827 40
33. CD Hoang J D'Cunha MG Kratzke CE Casmey SP Frizelle MA Maddaus 2004 Gene expression profiling identifies matriptase overexpression in malignant mesothelioma Chest 125 1843 52
34. GJ Gordon RV Jensen LL Hsiao SR Gullans JE Blumenstock WG Richards 2003 Using gene expression ratios to predict outcome among patients with mesothelioma J Natl Cancer Inst 95 598 605
35. R Govindan RA Kratzke JE Herndon 2nd GA Niehans R Vollmer D Watson 2005 Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B Clin Cancer Res 11 2300 4
36. A Mathy P Baas O Dalesio N. van Zandwijk 2005 Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50 83 6
37. F Lopez-Rios S Chuai R Flores S Shimizu T Ohno K Wakahara 2006 Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction Cancer Res 66 2970 9
38. E Suzuki S Kim HK Cheung MJ Corbley X Zhang L Sun 2007 A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection Cancer Res 67 2351 9
39. N Usami T Fukui M Kondo T Taniguchi T Yokoyama S Mori 2006 Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients Cancer Sci 97 387 94